Breakfast vs. fasting: new study tests how a meal changes drug levels

NCT ID NCT06415045

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial in 18 healthy adults tested whether eating a high-fat, high-calorie meal changes how the body absorbs a single 18 mg dose of Nerandomilast (BI 1015550). Participants took the drug either after fasting overnight or right after a heavy meal, and researchers measured drug levels in the blood. The goal is to understand if food affects the drug's concentration, which will guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nerandomilast (BI 1015550, JASCAYD®)
What this could lead to: If successful, this study will show whether Nerandomilast should be taken with or without food, helping guide future dosing instructions.
What could go wrong: This is a very early, small study in healthy people, not patients. Results may not predict effects in the intended disease population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

CRS Clinical Research Services Berlin GmbH

Berlin, 13627, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.